The Effects of Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention
Status:
Unknown status
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
- The purpose of this study is to examine the effects of tirofiban on platelet function
the Ultegra RPFA in diabetic patients undergoing elective coronary angioplasty and
stenting already treated with high loading dose (600mg) clopidogrel.
- About 44 people will be in the study. The study duration is a single hospitalization
period during which the angioplasty will be performed in addition to a 30-day post
hospitalization follow-up period.
- Patients taking part in the study will be assigned by chance into two groups.
- Group 1: patients will be treated with the glycoprotein inhibitor, Tirofiban
(25mcg/kg over 3 min bolus dose and 0.15 mcg/kg/hr for 12-24 hours), started
immediately after insertion of the sheath.
- Group 2: patients will be treated with equivalent placebo
All patients will be loaded with 600 mg clopidogrel at least 4 hours prior to scheduled
intervention.
All patients will have platelet function analyses at baseline and following treatment.